TRML TOURMALINE BIO INC

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference:

Jefferies Global Healthcare Conference, New York

Corporate Presentation

Thursday, June 6, 2024 at 2:30 pm ET

A live webcast and replay will be posted under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at .

About Tourmaline Bio, Inc. 

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is TOUR006.

About TOUR006

TOUR006 is a long-acting, fully human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. TOUR006 has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing TOUR006 in TED and ASCVD as its first two indications, with additional diseases under consideration.

Contact:

Meru Advisors

Lee M. Stern





EN
23/05/2024

Underlying

TRMLTOURMALINE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TOURMALINE BIO INC

 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio to Present at the Jefferies Global Healthcare Conferenc...

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference: Jefferies Global Healthcare Conference, New YorkCorporate PresentationThursday, June 6, 2024 at 2:30 pm ET A live webcast and replay will be...

May 23, 2024 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovas...

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial – First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in the first half of 2025 with potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases – – TRANQUILITY trial intended to provide evidence of TOUR006’s best-in-class potential...

May 16, 2024 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent...

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights – Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – – Expanded Thyroid Eye Disease (TED) clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Completed underwritten follow-on public offering in January 2024, raising gross proceeds of $172.5 million – – Ended the quarter...

May 13, 2024 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Res...

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights – Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Reached alignment with the U.S. FDA on the clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) in 2023 and received clearance for Investigational New Drug application (IND) in March 2024 – – Completed reverse merger with Talaris Therapeutics in Octob...

March 19, 2024 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio to Present at Upcoming Investor Conferences

Tourmaline Bio to Present at Upcoming Investor Conferences NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will participate in the following investor conferences in March. Jefferies Biotech on the Bay Summit, MiamiOne-on-one and Small Group Meetings March 12, 2024 Leerink Global Biopharma Conference, MiamiCorporate Present...

February 27, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch